Fulranumab (AMG-403) is a humanised monoclonal antibody targeting nerve growth factor (NGF), which blocks the binding and activation of NGF with TrkA and p75NTR and has analgesic effects, and can be used for the study of chronic pain.

Methods:
Various concentrations of Fulranumab (5–200 μg/mL) were used to evaluate its ability to inhibit anti-Fulranumab antibodies and false-positive anti-drug antibodies (ADA) induced by acid-treated NGF.
Results:
Fulranumab at 200 μg/mL (60 minutes) completely inhibited 10 ng/mL of anti-Fulranumab antibodies and suppressed 100 and 1,000 ng/mL antibodies by over 90%.[1] Fulranumab at 5–100 μg/mL partially and dose-dependently inhibited false-positive ADA responses.[1]